Q3 2023 results - Tuesday, October 24, 2023
Media release:
English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB) | Français (PDF 0.5 MB)
Interim financial report (PDF 0.6 MB)
Download the podcast (MP3 33 MB)
Download the presentation (PDF 3.5 MB)
Novartis Q3 2023 Impact and Sustainability Update (PDF 1.0 MB)
| Key figures1 | Continuing operations2 | ||
|---|---|---|---|
| Q3 2023 (USD m) | Q3 2022 (USD m) | % change (USD/cc) | |
| Net sales | 11,782 | 10,492 | 12 (cc: 12) |
| Operating income | 1,762 | 1,826 | -4 (cc: 13) |
| Net income | 1,513 | 1,330 | 14 (cc: 37) |
| EPS (USD) | 0.73 | 0.61 | 20 (cc: 45) |
| Free cash flow | 5,043 | 4,054 | 24 |
Core | |||
| Operating income | 4,405 | 3,772 | 17 (cc: 21) |
| Net income | 3,585 | 3,035 | 18 (cc: 23) |
| EPS (USD) | 1.74 | 1.40 | 24 (cc: 29) |
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
- As defined on page 37 of the Condensed Interim Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities and Discontinued operations include operational results from the Sandoz business.